FDA approves Innoviva’s bacterial pneumonia treatment

by user


The Food and Drug Administration said Tuesday that it approved Innoviva’s

Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.

The federal regulator said Xacduro, which treats ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia, is hard to treat and poses a great threat to human health.

The FDA granted approval of Xacduro, administered by intravenous infusion, to Entasis Therapeutics, acquired by the pharma company Innoviva last year.


Source link

Related Posts

Leave a Review

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy